Pharma dominates in climate scorecard; FDA hears need for opioid REMS;

> AstraZeneca and Johnson & Johnson led the pharmaceutical industry in besting 13 other industries on the nonprofit Climate Counts' climate change scorecard, which measures corporate efforts to reduce emissions. Report l Release

> Steve Hayes, director of Novus Medical Detox Center, and Larry Golbom, host of The Prescription Addiction Radio Show testified before the FDA in late May about the need for Risk Evaluation Mitigation Strategies (REMS) for opioids, especially OxyContin. Release

> GlaxoSmithKline has opened a $600 million ($414 million US) vaccine manufacturing plant as part of a 10-year strategy. Article

> Contract manufacturer CoreRx will purchase an 80,000-square-foot facility in Florida for the formulation, analysis and production of clinical trial quantities of pharmaceuticals. Article

> Formulation development and clinical trial materials maker Metrics has consolidated its quality-related operations and promoted Tom Wilson to VP for quality operations. Announcement

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.